Ensysce Biosciences posts investor presentation on trypsin-controlled opioids with abuse, overdose protection

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC

0.00
  • Ensysce Biosciences outlined a planned US pain franchise built around its trypsin-controlled TAAP platform for abuse deterrence, led by PF614, an oxycodone prodrug.
  • The company positioned PF614 for acute severe post-surgical pain, citing a Phase 3 abdominoplasty study initiated in 2025 as the pivotal trial intended to support an NDA in 2027.
  • A second Phase 3 study in bunionectomy was slated to start in 2026 to expand the safety database.
  • For chronic pain, Ensysce highlighted PF614-MPAR, which combines PF614 with the trypsin inhibitor nafamostat to limit oxycodone release at higher dose-unit exposure as an overdose-mitigation approach.
  • The pipeline also includes TAAP-based candidates in ADHD and opioid use disorder, alongside MPAR-related work in infectious and respiratory diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.